The following is an interview with Dr Toni K. Choueiri, medical oncologist at the Dana-Farber Cancer Institute, Boston, US, about the kidney cancer highlights from the European Society of Medical Oncology (ESMO) 2017 conference in Madrid, Spain this week. During this interview he talks about the updated CABOSUN (cabozantinib versus sunitinib) clinical trial results, updated CheckMate-214 (nivolumab plus ipilimuab versus sunitinib) results, and the role of cytoreductive nephrectomy in patients with advanced kidney cancer (SURTIME and CARMENA trials).

See the interview on Practice Update here